Replies to post #428464 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

But Bas says the outcome of the P2b/3 AD is never before seen amazing, doesn’t that make you wrong 😑

[12x]

Perhaps the whole proper dose issue is a bigger problem in old people. I think he's waiting for Rett to finally release the full topline data, hoping a Rett win will blunt the 2b tie.. I've kept a small position for the Rett readout. The phase 3 AD readout won't be until 2026 or 2027 at this rate.

The PDD phase 2 patients are actually older than AD 2b/3 patients. It’s a surprise AD trials had a proper dose issue. Clearly AD patients are more fragile than PD.

Waiting for Rett is correct strategy imo. Rett has better chance to succeed. If Rett succeeds, it can be used as either off-label use or a tiebreaker for AD. Even if Rett TLR not a clear cut success, Anavex has the short PD p3 trial to fall back to.

There is no reason to risk precious capital on the hardest indication knowing other easier indications are out there. AD was a wrong indication to work on first imo.